The role of targeted therapy for gastrointestinal tumors

Giuseppe Bronte, Antonio Russo, Francesco Passiglia, Konstantinos Papadimitriou, Eugenio Fiorentino, Marc Peeters, Konstantinos Papadimitriou, Antonio Russo, Giovanni Sortino, Francesco Passiglia, Eugenio Fiorentino, Christian Rolfo, Giuseppe Bronte, Ghada Marogy, Giovanni Sortino

Risultato della ricerca: Articlepeer review

27 Citazioni (Scopus)


Many targeted drugs have been studied to target the molecular pathways involved in the development of gastrointestinal cancers. Anti-VEGF, anti-EGFR agents, and recently also multi-kinase inhibitor regorafenib, have already been available for the treatment of metastatic colorectal cancer patients. To date, Her-2 positive, gastric cancer patients, are also treated with trastuzumab, while the multi-targeted inhibitor, sorafenib, represents the standard treatment for hepatocellular carcinoma patients. Finally, sunitinib and everolimus, have been approved for the treatment of the neuroendocrine gastroenteropancreatic tumors. Actually a great number of further drugs are under preclinical and clinical development. The aim of this review is to provide a comprehensive overview of the state of art, focusing on the new emerging strategies in the personalized treatment of gastrointestinal tumors.
Lingua originaleEnglish
pagine (da-a)875-885
Numero di pagine11
Stato di pubblicazionePublished - 2014

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2721???
  • ???subjectarea.asjc.2700.2715???


Entra nei temi di ricerca di 'The role of targeted therapy for gastrointestinal tumors'. Insieme formano una fingerprint unica.

Cita questo